Clinical Trial

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in…

12 months ago

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a…

12 months ago

GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series

- Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM…

12 months ago

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13th at 2:00 PM ETBERWYN, Pa., July 05, 2023 (GLOBE NEWSWIRE) -- Panavance…

12 months ago

AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Wednesday, July 12th at 11:00 AM ETOCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM…

12 months ago

Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors

NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…

12 months ago

Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic…

12 months ago

Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the…

12 months ago

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of…

12 months ago

Spectral Medical Announces the Opening of Three Additional Tigris Clinical Trial Sites

University of Alabama enrolls patient 65 after second day of opening for enrollmentTORONTO, July 05, 2023 (GLOBE NEWSWIRE) -- Spectral…

12 months ago